Strand Therapeutics

@Nasdaq helped us in celebrating our Series B with a billboard in the heart of Time Square! Thank you to our friends at Nasdaq for your support on our mission to create cures for patients!

mRNA therapeutics are a powerful modality. It's also one where you can’t take shortcuts if you want to succeed, and circular RNA (circRNA) is no different. In a new interview with @PharmaScrip’s @awmcconaghie, our co-founder, President, and Head of R&D @tasuku_kitada breaks down what it takes to build an in vivo CAR-T platform that can deliver in the clinic: optimized circRNA architecture, targeted lipid nanoparticle (LNP) delivery, and programmable safety controls built directly into the construct. With major pharma bets pouring into the space, Tasuku makes the case that the companies that win will be the ones that did the engineering work before rushing to the clinic. Read more: insights.citeline.com/scrip/advanced…

Circular RNA is emerging as one of the most exciting frontiers in gene and cell therapy. At Strand, we've been building on it for years. BioWorld's @MarJungle covered the latest advances at #ASGCT2026, including a conversation with our co-founder, President, and Head of R&D @tasuku_kitada. They discuss how Strand is using circRNA to power STX-005, our in vivo CAR-T program designed to be a redosable, off-the-shelf approach to cell therapy. Read more: bioworld.com/articles/73126…

Strand stays committed to fostering the next generation of scientists. Shoutout to Strands Eloise, Gautam and Daniel for participating as judges for the MSEF Middle School Science Fair this past weekend!

Programmable RNA is coming for in vivo CAR-T. Tomorrow at #ASGCT2026, our Principal Scientist Ashlesha Odak, Ph.D. is presenting preclinical NHP data showing how programmable circRNA, combined with a targeted LNP approach, can generate functional CAR-T cells in vivo with integrated safety controls. No cell extraction, no manufacturing facility. This is pioneering what's possible in programmable genetic medicine. Watch the presentation to find out for yourself: 📢 LNPs for in vivo CAR-T applications 📅 Tuesday, May 12, at 9:00-9:15 am ET 📍 MCEC Room 210 ABC (Level 2) Presentation abstract can be found here: annualmeeting.asgct.org/abstract

Our CEO @DrSynbio sat down with @FierceBiotech’s @Angus_Fierce to talk about the regulatory and manufacturing barriers slowing first-in-human clinical trials in the U.S., and what a more efficient pathway to first-in-human trials could mean for American patients. Read the conversation here: fiercebiotech.com/biotech/concer…

You can find the full agenda here: syntheticbiologysummit.com/2026/sessions

How are advances in sequence design, delivery, and manufacturing closing the gap between computational insight and real-world medicines? Join @tasuku_kitada, co-founder, President, and Head of R&D at Strand Therapeutics, at @SynBioBeta on Wednesday, May 6, for a panel on one of the most important questions in programmable medicine. We hope to see you there!

Strand Therapeutics is heading to the @MilkenInstitute Global Conference 2026 in Los Angeles. On May 4 at 10 a.m. PT, our CEO and co-founder, @DrSynbio, will join an invitation-only panel on sustaining American leadership in biomedical innovation. He’ll be joined by @SecAzar, 24th U.S. Secretary of Health and Human Services; @mmrozenman, CFO and CBO of @insitro; and @rtnarch, co-founder and managing director of ARCH Venture Partners. The session will be moderated by @SungHeeTweets, managing director of FasterCures at Milken Institute Health. Looking forward to continuing the conversation at #MIGlobal. milkeninstitute.org/content-hub/ev…

We're excited to welcome Kunal Bhatia to Strand as Chief Financial Officer. Kunal brings 15 years of investment banking experience advising biopharmaceutical companies on financing and business development, most recently as interim CFO and CBO to a portfolio of life sciences companies. His appointment comes as Strand advances a growing pipeline – STX-001 clinical data, STX-003 heading to the clinic in mid-2026, and our in vivo CAR-T program – and builds on a $153M Series B. As we enter this next chapter, Kunal's expertise in capital formation and strategic partnerships positions Strand to keep advancing our mission of integrating programmable genetic medicines into the core of modern therapeutics. Read more: businesswire.com/news/home/2026…

Generating CAR-T cells inside the body, without removing and reengineering a patient's cells, has long been one of cell therapy's most persistent unsolved challenges. We're presenting data at #ASGCT2026 with data that shows how programmable mRNA can deliver on it. Ashlesha Odak, PhD will go over preclinical findings from the circRNA-LNP platform showing near-complete B cell depletion in non-human primates following IV dosing, with programmable safety controls built in. Presentation details below. Full abstract here: annualmeeting.asgct.org/abstracts Abstract Title: Programmable circRNA-tLNP platform enables efficient in vivo CAR-T cell programming and robust activity in a NHP model Session Type: Oral Session Name: LNPs for in vivo CAR-T applications Date and Time: Tuesday, May 12, 2026, at 9:00-9:15 am ET Location: MCEC Room 210 ABC (Level 2)

@DrSynbio @EY_US Read more here: ey.com/en_us/entrepre…

Congratulations to our co-founder and CEO @DrSynbio, named a finalist for the @EY_US Entrepreneur Of The Year 2026 New England Award. Jake built Strand on a single conviction: mRNA could be programmed to know the difference between healthy and diseased cells. That idea is what this recognition reflects, and what we believe the future of genetic medicine will be built on. Congrats, Jake!

Happy belated Earth Day from Strand Therapeutics! 🌎 Strands celebrated by taking public transit to work, swapping disposable cups and bottles for reusable bottles, eating plant based, donating clothing, and cleaning up litter near our office!

@Annals_Oncology @jasonlukemd Read more: annalsofoncology.org/article/S0923-…

What does it take to make immunotherapy safer for every patient? A new manuscript in @Annals_Oncology co-authored by our CMO @jasonlukemd takes on a piece of that puzzle: how Cytokine Release Syndrome (CRS) is graded and reported in trials. The authors call for granular, symptom-driven reporting to cut diagnostic ambiguity and enable safety comparisons across global trials. As Strand advances our own therapies into solid tumors and beyond, building the right safety infrastructure as the field scales is essential.

How do we at Strand turn ideas and insights into scalable, revolutionary genetic medicines? @ashleevance and @corememory visited the @StrandTx team in Boston to learn how we did it. See for yourself: youtube.com/watch?v=pN-ykH…

#WorldHealthDay reminds us that science saves lives. From basic research to the clinic, our field drives critical breakthroughs to reach patients who need them most. Science earns trust through transparency, results and the relentless pursuit of better answers. We #StandWithScience because patients are waiting.

🎥 Watch now: @ashleevance and the @corememory spent a day at Strand headquarters with CEO and co-founder @DrSynbio and our scientists. The video offers a closer look at our programmable mRNA-based therapies for cancer and autoimmune diseases. Initial clinical results indicate our STX-001 therapy has destroyed melanoma tumors in patients who had no other options left. Years of work in the lab have led to this moment. And we're just getting started. You can find the full video here: youtube.com/watch?v=pN-ykH…

Thanks, @ashleevance for visiting Strand Therapeutics and speaking with our co-founder and CEO @DrSynbio and the team about mRNA's next chapter. Tune in and learn where the technology is headed next, starting with the fight against cancer.

As Autoimmune Awareness Month comes to a close, it's important to continue the conversation around what makes these diseases so difficult to solve. Autoimmune conditions are caused by the immune system misfiring, attacking the healthy tissue it was designed to protect. More than 50 million Americans live with these chronic diseases, many waiting years and seeing doctor after doctor before getting an answer. Our challenge for the future lies in learning how to redirect the immune system without silencing it altogether. Precision is the problem, and that’s the direction medicine needs to move. #AutoimmuneAwarenessMonth